UB Paderborn / Katalog / Suche / in CDI

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

The lancet oncology, 2017-04, Vol.18 (4), p.446-453

2017

Volltextzugriff (PDF)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Journal of clinical oncology, 2023-01, Vol.41 (2), p.186-197

2023

Volltextzugriff (PDF)

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Journal of clinical oncology, 2020-01, Vol.38 (3), p.214-222

2020

Volltextzugriff (PDF)

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

Journal for immunotherapy of cancer, 2016-11, Vol.4 (1), p.76-76, Article 76

2016

Volltextzugriff (PDF)

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.77-77, Article 77

2016

Volltextzugriff (PDF)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002990

2021

Volltextzugriff (PDF)

Melanoma: a model for testing new agents in combination therapies

Journal of translational medicine, 2010-04, Vol.8 (1), p.38-38, Article 38

2010

Volltextzugriff (PDF)

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Pigment cell and melanoma research, 2015-03, Vol.28 (2), p.135-147

2015

Volltextzugriff (PDF)

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Journal of translational medicine, 2022-06, Vol.20 (1), p.253-253, Article 253

2022

Volltextzugriff (PDF)

Ocular adverse events in PD-1 and PD-L1 inhibitors

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002119

2021

Volltextzugriff (PDF)

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Journal for immunotherapy of cancer, 2024-07, Vol.12 (7), p.e009074

2024

Volltextzugriff (PDF)

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

Gynecologic oncology, 2007-09, Vol.106 (3), p.453-460

2007

Volltextzugriff (PDF)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003569

2022

Volltextzugriff (PDF)

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Blood, 2018-11, Vol.132 (Supplement 1), p.705-705

2018

Volltextzugriff (PDF)

45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A52-A52

2023

Volltextzugriff (PDF)

MHC and the Power of P

JNCI cancer spectrum, 2021-02, Vol.5 (1)

Streicher, Howard

2021

Volltextzugriff (PDF)

88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A96-A96

2021

Volltextzugriff (PDF)

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A402-A404

2021

Volltextzugriff (PDF)

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A95-A95

2021

Volltextzugriff (PDF)

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e004310

2022

Volltextzugriff (PDF)

644 Ocular adverse events associated with programmed death-1 and programmed death ligand-1 immunotherapy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A681-A681

2020

Volltextzugriff (PDF)

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4089-4099

2005

Volltextzugriff (PDF)

Immune checkpoints in cancer clinical trials

Ai zheng, 2014-09, Vol.33 (9), p.434-444

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Melanoma: a model for testing new agents in combination therapies

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Ocular adverse events in PD-1 and PD-L1 inhibitors

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

MHC and the Power of P

88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

644 Ocular adverse events associated with programmed death-1 and programmed death ligand-1 immunotherapy

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Immune checkpoints in cancer clinical trials

Suchergebnisse filtern